Medexus Pharmaceuticals (TSE:MDP) Sets New 52-Week High – Should You Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP)’s share price hit a new 52-week high on Thursday . The company traded as high as C$3.83 and last traded at C$3.84, with a volume of 84289 shares changing hands. The stock had previously closed at C$3.60.

Wall Street Analyst Weigh In

Several brokerages have commented on MDP. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday. Leede Financial set a C$8.25 target price on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Finally, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, Medexus Pharmaceuticals has an average rating of “Strong Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Price Performance

The company has a market cap of C$99.10 million, a PE ratio of 80.80 and a beta of 1.96. The company has a 50-day moving average price of C$2.77 and a two-hundred day moving average price of C$2.53.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.